Last updated: March 2, 2026
What is the Drug and Market Scope?
NDC 00054-0018 references Vardenafil Oral Tablets, 20 mg, marketed primarily as Levitra. It is used for erectile dysfunction treatment. The drug faces competition from generic Vardenafil versions and other PDE5 inhibitors such as Sildenafil (Viagra) and Tadalafil (Cialis).
Market Size and Trends
Current Market Dynamics
- Global Erectile Dysfunction (ED) Drug Market was valued at approximately USD 4.8 billion in 2022.
- The market is expected to grow at a CAGR of 7% from 2023-2030, reaching around USD 8.2 billion.
- North America accounts for roughly 40% of the market, followed by Europe (25%) and Asia (20%).
Patent and Generic Entry Timeline
- Original Levitra patent expired in 2018 in the U.S., allowing multiple generics to enter.
- The FDA approved at least three generic Vardenafil products in 2018-2020.
- Specific to NDC 00054-0018, its exclusivity period appears to have ended in 2018, leading to increased generic competition.
Pricing History and Projections
Historical Pricing Data
| Year |
Brand Name (Levitra) |
Average Wholesale Price (AWP) per 20 mg tablet |
| 2017 |
Levitra |
$25 |
| 2018 |
Brand price drops |
$18 |
| 2018-2022 |
Generics enter |
$4-6 |
Current Price Range
- The retail price for the brand Levitra varies between $20-25 per tablet.
- Generic Vardenafil prices range from $4-6 per tablet, with some pharmacies offering lower cash prices.
Projected Price Trends (Next 5 Years)
- The brand's price will likely decline to under $10 per tablet by 2024 due to increased generic competition.
- Brand-name Levitra may maintain a premium of 2-3 times over generics until patent exclusivity ends completely.
- Prices for generic Vardenafil are projected to stay within the $3-5 range, with slight upward adjustments based on manufacturing costs and market demand.
Market Opportunities and Risks
Opportunities
- Growing prevalence of ED, especially among aging males and those with comorbidities such as hypertension and diabetes.
- Increased acceptance of oral ED medications in emerging markets.
Risks
- Price erosion from low-cost generics.
- Potential new entrants or biosimilars that could further lower prices.
- Shifts in prescribing practices, including off-label use of alternative therapies.
Competitive Landscape
| Competitors |
Market Share |
Key Differentiators |
Price Position |
| Brand Levitra |
20% |
Brand recognition, physician trust |
~$20-25 per tablet |
| Generic Vardenafil |
75% |
Lower price point |
$4-6 per tablet |
| Others (Tadalafil, Sildenafil) |
5% |
Different duration and side effect profiles |
$3-10 per tablet |
Regulatory and Policy Factors
- The expiration of patent exclusivity accelerated the availability of generics.
- Price controls and reimbursement policies in different countries influence retail prices.
- FDA approvals of biosimilars or new formulations could impact market share and prices.
Implications for Stakeholders
- Pharmaceutical companies should focus on maintaining market share via cost-effective manufacturing.
- Investors looking at generic manufacturers could see declining prices but heightened volume sales.
- Healthcare providers may favor generics due to lower costs, reducing revenues for brand-name drugs.
Key Takeaways
- After patent expiry in 2018, NDC 00054-0018 (Levitra) transitioned to a predominantly generic market.
- Retail prices for generics are expected to stabilize around $4-6 per tablet over the next five years.
- The overall ED drug market continues to grow at a steady pace, driven by demographic trends and expanded global access.
- Price erosion for brand Levitra will persist until complete market saturation with generics.
- Market entrants should monitor patent litigation, regulatory changes, and reimbursement policies for pricing insights.
FAQs
1. Will the price of Levitra ever return to its pre-2018 levels?
Unlikely; patent expiration and increased generics have permanently lowered the brand's market premium.
2. How does the price of Vardenafil compare to other ED drugs?
Vardenafil generally costs more than Sildenafil or Tadalafil, but generic versions reduce this gap significantly.
3. Are biosimilars or alternative formulations expected to impact the market?
No, as Vardenafil is a small molecule, not a biologic; biosimilars are not applicable. However, new formulations or delivery systems could influence pricing.
4. What is the main driver of price decline for NDC 00054-0018?
Market saturation with generics following patent expiration and increased manufacturing capacity.
5. How should stakeholders exploit this market?
By focusing on cost-efficient production, expanding into emerging markets, and differentiating through formulations or delivery methods.
References
[1] Global Market Insights. (2022). Erectile Dysfunction Drugs Market Size, Share & Trends.
[2] IQVIA. (2022). US Prescription Trends for Erectile Dysfunction Medications.
[3] FDA. (2018). Approval of Generic Vardenafil.
[4] IMS Health. (2018). Pricing and Market Access Data for ED Drugs.
